Cardiff Oncology Q1 2022: cash $129.4M; mCRC trial shows improved ORR/PFS vs historical controls

Cardiff Oncology, Inc.

2022-Q1 EPS reported -$0.25 revenue$74,000

Cash, equivalents & short-term investments ~$129.4M as of Mar 31, 2022; net cash used in ops $10.2M.
R&D expense $7.2M (up $3.9M YoY); SG&A $3.9M (up $1.7M YoY) on higher CMC, headcount, stock comp.
Phase 1b/2 mCRC: 34% initial ORR, 29% confirmed at RP2D (15 mg/m²) vs historical 5-13%; mPFS 9.4 months across all doses.
Phase 2 mCRPC: 75% disease control at 12 weeks in highest dose-density arm; mutations in PTEN/MTOR linked to response.
Preclinical: onvansertib+olaparib showed significant survival benefit vs each alone in PARPi-resistant ovarian PDX models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.